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Abstract 
 
Health Outcomes of Statin Users Compared to Non-Users with 
Clostridium difficile Infection 
 
Jacqueline Rose Argamany, M.S.P.S. 
The University of Texas at Austin, 2017 
 
Supervisor:  Kelly R. Reveles 
 
Background: Clostridium difficile infection (CDI) is the most common cause of 
nosocomial diarrhea, and the primary cause of healthcare-associated infections in the 
United States. Statins have beneficial effects independent of their lipid-lowering effects; 
these pleiotropic effects may include anti-inflammatory and immunomodulatory activity. 
The potential role for statins in CDI is unique in that both the cholesterol-lowering and 
pleiotropic effects of statins could lead to improvements in clinical response for patients 
with CDI.  
Rationale: Limited data currently exist in the literature on the outcomes of statin 
users who develop CDI compared with non-users. The primary objective of this study was 
to compare CDI health outcomes in statin users and non-users in a national cohort of 
patients from a single-payer health system.   
Methods: This was a longitudinal, retrospective cohort study of all adult CDI 
patients receiving care from the Veterans Health Administration. Patients were divided into 
two groups based on statin exposure prior to and during the first CDI encounter. For the 
 vii 
primary analysis, we created a propensity score-matched cohort to account for variables 
associated with indications for statin use. Once the matched cohort was derived, additional 
variables known to impact CDI outcomes were entered into a multivariable logistic 
regression model in order to determine the risk of individual CDI outcomes. 
Results: CDI outcomes were evaluated for statin users and non-users before and 
after propensity score-matching. In the unmatched cohort, statin use was significantly 
associated with reduced risk of 30-day mortality (aOR 0.60, 95% CI 0.36-1.00, p=0.0478). 
In the matched cohort, statin use remained significantly associated with a reduced risk of 
30-day mortality (aOR 0.45, 95% CI 0.23-0.88, p=0.0198). No significant trends were 
found for inpatient mortality, 60-day recurrence, and severe or complicated CDI. 
Conclusion: This is the largest study comparing CDI health outcomes among statin 
users and non-users. Statin users were found to have significantly reduced 30-day mortality 
in both an unmatched and matched patient cohort compared to non-users. While these data 
support previous findings reported in the literature, no change in routine care of CDI 
patients can be recommended at this time.  
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Chapter One: Clostridium difficile Infections 
MICROBIOLOGY AND PATHOGENESIS 
Clostridium difficile is a Gram-positive, spore-forming, anaerobic bacterium. Its 
name reflects the difficulty in isolating the organism and its slow growth in culture.1,2 This 
species can become a natural colonizer of the human gastrointestinal (GI) tract after 
exposure to the spores via the fecal-oral route of transmission. C. difficile is clinically 
significant for its association with antibiotic-associated diarrhea.3,4 Specifically, C. difficile 
infection (CDI) is the most common cause of nosocomial diarrhea, and more recently, 
became the primary cause of healthcare-associated infections in the United States (US).  
C. difficile is a non-invasive organism and infections due to this organism are 
primarily localized to the GI tract.3 Many people are colonized with non-toxigenic strains 
of C. difficile that are not known to cause disease and may be protective against infection 
with toxigenic strains.5,6 Disruption of the gut microflora due to broad-spectrum antibiotic 
therapy is the most significant risk factor for the development of CDI.4,7 Following this 
disruption, exposure to C. difficile spores in the environment leads to colonization and 
proliferation of C. difficile.8 Disease develops when the bacteria produces toxins that elicit 
an inflammatory response (Figure 1).9 Symptoms of CDI can include diarrhea, 
dehydration, fever, leukocytosis, and in severe cases, complications may include prolonged 
ileus, toxic megacolon, septic shock, intestinal perforation, and death.8,9 
 
 
 
 
 2 
Figure 1. Pathophysiology of CDI9 
 
C. difficile is known to produce three toxins in the body: Toxin A (tcdA), Toxin B 
(tcdB), and binary toxin.5,6 Toxins produced and the amount of toxin produced vary 
amongst different strains of C. difficile. Toxins A and B are known to be the primary 
virulence factors associated with C. difficile.6 Toxin A acts primarily as an enterotoxin, 
causing local tissue injury and inflammation. Toxin B acts primarily as a cytotoxin by 
killing the GI cells. The effects of these toxins are due to their work as glucosyltransferases 
to inactivate regulatory pathways mediated by the Rho family of guanosine triphosphatases 
(Rho GTPases).5,6 These Rho GTPases are proteins involved in cytoskeleton structure and 
signal transduction, and their inactivation ultimately leads to cell apoptosis, the loss of 
intestinal barrier integrity, and neutrophilic colitis (Figure 2).5 Binary toxin is a more recent 
discovery, and its effect on the pathogenicity of C. difficile is not fully understood.10 
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Clinical expression of disease depends on virulence of the infecting strain and the host’s 
immune response.8 Virulence of an infecting strain is often attributed to increased toxin 
production as compared to less pathogenic strains. Additionally, there is evidence that 
asymptomatic C. difficile carriers and immune system production of toxin A antibodies are 
protective against severe CDI.4,11   
 
Figure 2. Effects of C. difficile Toxins A and B on Intestinal Cells5 
 
 
Unfortunately, the treatment for CDI requires therapy with oral antibiotics, such as 
metronidazole and vancomycin, which can further disrupt the balance of GI flora.8 It can 
take weeks to months for patients to recover from infection and restore normal flora.12 In 
that time, patients are susceptible to recurrent CDI, either by reinfection of C. difficile 
through spore exposure or by relapse of the initial infection due to hidden spores 
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germinating.13 Other risk factors for CDI include older age (≥65 years), prolonged 
hospitalization, severe underlying illness, inflammatory bowel disease, and GI surgery or 
manipulation.4,7,8,14 In addition to antibiotics, the use of other medications such as 
immunosuppressants, gastric acid suppressants, antineoplastic agents have been associated 
with CDI.  
 
DIAGNOSIS 
Diagnosis of CDI relies on a combination of clinical suspicion and laboratory 
testing (Table 1).14,15 Healthcare providers should have a strong suspicion of CDI based on 
patient symptoms or imaging prior to sending stool samples for testing. Laboratory testing 
can involve multi-step algorithms which incorporate a glutamate dehydrogenase (GDH) 
antigen testing step to screen patients for CDI followed by a toxin assay or polymerase 
chain reaction (PCR) test for toxin genes for confirmation of diagnosis.  
 
Table 1. Laboratory Testing for Diagnosis of CDI 
Test Detects Advantages Disadvantages 
Stool culture Bacteria High sensitivity Slow turnaround 
Toxin assay Toxins Rapid turnaround Moderate sensitivity  
GDH testing Antigen Rapid turnaround Screening only 
PCR Toxin genes Rapid turnaround 
High sensitivity 
False positives 
 
GUIDELINE RECOMMENDED TREATMENT 
In 2010, the Infectious Diseases Society of America (IDSA) published guidelines 
for the treatment and prevention of CDI.14 Current IDSA CDI guidelines recommend 
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treatment based on CDI type and severity (Table 2). Severe CDI is defined as leukocytosis 
with a white blood cell (WBC) count ≥15,000 cells/µL or an increase in serum creatinine 
to greater than 1.5 times the baseline level. The guidelines further classify patients as 
“complicated” if they have hypotension or shock, ileus, or toxic megacolon. Infections 
complicated by toxic megacolon, intestinal perforation, or necrotizing colitis can require 
emergency surgical procedures, including a total or partial colectomy.  
It is recommended that patients who experience CDI for the first time be treated 
with metronidazole or oral vancomycin.14,15 Recent studies have shown that vancomycin 
is superior to metronidazole in treating severe disease; thus, oral vancomcyin is currently 
recommended for severe CDI.8,16 First recurrences are generally treated with the same 
agent used for the initial episode, but oral vancomycin is preferred for severe recurrences. 
After receiving approval from the U.S. Food and Drug Administration (FDA) in 2011, 
fidaxomicin gained notoriety as the first new antibiotic indicated for CDI in 25 years.8 Data 
from clinical trials have shown fidaxomicin is non-inferior to vancomycin for mild to 
moderate CDI and may be more effective than vancomycin at preventing disease 
recurrence.17,18 
 
Table 2: Guideline Recommended CDI Treatment Regimens  
Clinical definition Recommended treatment 
Initial episode: Mild or moderate Metronidazole 500 mg oral q8h x 10-14 days 
Initial episode: Severe Vancomycin 125 mg oral q6h x 10-14 days 
Initial episode: Complicated 
Vancomycin 500 mg oral q6h PLUS 
Metronidazole 500 mg IV q8h x 10-14 days 
Optional: vancomycin enema for rectal instillation 
First recurrence Same as initial episode, unless severe 
Second recurrence Pulsed or tapered vancomycin Fidaxomicin 200 mg oral q12h x 10 days* 
*Not recommended in 2010 guidelines due to FDA-approved in 2011 
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ADDITIONAL TREATMENT OPTIONS 
There are non-antibiotic therapies that may be used for the treatment of CDI; 
however, these have limited effectiveness data. Current research has focused heavily on 
finding ways to restore the natural balance of the gastrointestinal microbiome, by 
adjunctive treatment with probiotics and more recently in controlled trials of fecal 
microbiota transplantation (FMT).9,19-21 Theoretically, probiotics could improve CDI 
outcomes by altering the gut flora, providing antimicrobial activity and intestinal barrier 
protection, and immunomodulation; however, evidence of clinical significance and 
recommendations for specific probiotic products remains debatable.14,22 Early trials of 
FMT have shown high rates of success in recurrent disease when donor feces are 
administered as a suspension via colonoscope, retention enema, or nasogastric tube to treat 
CDI recurrence.19-21  
Immune response to C. difficile is a major determinant of health outcomes among 
patients with CDI; therefore, immunomodulatory therapies, such as intravenous immune 
globulin (IVIG) and monoclonal antibodies might play a role in the treatment of CDI.8,14 
In 2016, bezlotoxumab (Zinplava®) was approved by the FDA as the first human 
monoclonal antibody that binds to C. difficile Toxin B.23,24 It must be used in conjunction 
with antibiotic therapy for CDI and is indicated to reduce recurrence of CDI in patients 
considered to be at high risk for recurrence. 
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Chapter Two: Statin Therapy in CDI 
POTENTIAL ROLE FOR STATINS 
A hypothetical but unique approach to the adjunctive treatment of CDI involves the 
use of statins for their myriad of effects on inflammatory pathways.25-27 Statins are 
reversible, competitive inhibitors of 3-hydroxyl-3-methylgutarul-coenzyme A (HMG-
CoA) reductase. Through this mechanism, statins are able to inhibit the rate-limiting step 
in cholesterol biosynthesis. They are used in the primary and secondary prevention of 
cardiovascular disease.28 During its first 15 years on the market (1996-2011), atorvastatin 
(Lipitor®) became the top selling prescription medication in the world.29 From 2007 to 
2010, data from the National Health and Nutrition Examination Survey showed that, 
among adults between the ages of 40-64 years, only 19% used a cholesterol-lowering 
medication while the rate was as high as 39% among adults 65-74 years of age.30 
The lipid-lowering effects of statins may play a role in CDI for two reasons. First, 
hyperlipidemia (HLD) is believed to cause a persistent, generalized inflammatory state of 
the body; one example of this is the elevation of biomarkers such as the C-reactive protein 
(CRP) seen in patients with atherosclerotic disease.26-28,31 With regard to CDI patients, 
those with pre-existing GI inflammation, such as that seen in patients with inflammatory 
bowel disease (IBD), are associated with poorer clinical outcomes, including recurrence 
and death.32-35 Additionally, these patients are also at an increased risk for CDI due to 
frequent healthcare exposures, gut microbiota dysbioses, and exposure to 
medications.32,36,37 Second, cholesterol contributes to the toxin activity of C. difficile. 
Specifically, cholesterol facilitates toxin binding to cells and is required for toxin 
penetration into the cells.38,39 In our own preliminary data, dyslipidemia [International 
Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) code 272] was 
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significantly associated with 60-day recurrence (55% vs. 49%, p<0.0001). Statins may also 
play a role in CDI therapy beyond the lipid-lowering effects described above.40  
Proposed pleiotropic effects of statins (non-cardiac benefits) date back to a post-
hoc analysis of the West of Scotland Prevention Study (1998).28 Patients taking pravastatin 
had improved survival despite similar cholesterol levels as compared with patients taking 
placebo. It was hypothesized that statins have beneficial effects independent of their lipid-
lowering effects. These pleiotropic effects of statins may include anti-inflammatory, 
immunomodulatory, antioxidant, and antithrombotic activity (Figure 3).41  
 
Figure 3. Pleiotropic Effects of Statins41 
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The mechanism responsible for these effects is likely related to a reduction in the 
synthesis of cholesterol intermediary products which leads to decreased activation of Rho 
GTPases, ultimately reducing the response of inflammatory intracellular signaling 
pathways (Figure 4).41 These pathways are of particular importance in patients with CDI 
due to the activation of these pathways by toxins A and B.5,6 
 
Figure 4. Statin Mechanism of Action41  
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The potential benefits associated with statins in observational studies are subject to 
a type of confounding or bias known as the healthy user effect.42,43 Prior studies have shown 
that statin users are more likely to live at home, stop smoking, receive better medical care, 
have health insurance, and be positively engaged in the healthcare system. This leads to 
controversy regarding any positive associations with statin use and clinical outcomes, in 
that statin use may not have direct effects on the disease in question and is merely an 
indicator of low-risk patients.40 Paradoxically, for a disease like CDI that is known to be 
associated with frequent healthcare exposure, statin use could potentially indicate patients 
more likely to be exposed to C. difficile spores in a healthcare setting. 
Researchers have extensively studied the impact of statin use in other infections, 
including pneumonia and sepsis, as well as other inflammatory conditions, such as chronic 
obstructive pulmonary disease (COPD) and multiple sclerosis; however, controversy 
remains regarding the addition of or the decision to continue statins in many disease 
specific situations. Estimating the effect of statin therapy on mortality from infection and 
sepsis is limited by the retrospective design of studies, high heterogeneity, and 
confounding. In a meta-analysis from 2014, Wan et al. determined that in 27 observational 
studies, statins were associated with a significant decrease in mortality (aRR 0.65, 95% CI 
0.57-0.75), but in five randomized controlled trials statins did not significantly decreased 
in-hospital mortality (RR 0.98, 95% CI 0.73-1.33) or 28-day mortality (RR 0.93, 95% CI 
0.46-1.89).44 The potential role for statins in CDI is truly unique in that both the cholesterol-
lowering and pleiotropic effects of statins could lead to improvements in clinical response 
for patients with CDI. Prior studies designed to assess the use of statins on CDI outcomes 
are limited and have been plagued by small sample sizes.45-47  
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STATINS AND INTESTINAL MICROFLORA 
Aside from the hypothetical benefits of statins in CDI due to the cholesterol-
lowering and anti-inflammatory effects of these agents, it is unknown if or how statins 
affect the natural GI flora. Alterations of the natural occurring balance of flora are seen in 
patients with inflammatory disease processes, obesity, diabetes mellitus, and high-fat 
diets.39,48,49 Specifically, decreases in Bacteroidetes and increases in Firmicutes and 
Proteobacteria have been described. Similar changes to the flora are seen in CDI, leading 
to the hypothesis that naturally high levels of Bacteroidetes are protective against CDI 
colonization and overgrowth.9,50,51 Theoretically, a diet high in cholesterol could increase 
a patient’s risk of CDI while statin therapy could have potentially protective effects on the 
GI microbiome, further complicating the role of statin therapy in CDI patients. 
 
STATINS AND CDI RISK 
Despite the potential benefits of statins on patients with CDI, few studies describe 
the effect, if any, of statin use on the risk of developing CDI. In 2011, Naggie et al. found 
a significantly decreased risk of CDI in statin users (OR 0.35, 95% CI 0.15-0.83) using a 
small case-control design.52 Of the 66 CDI cases, 27% were statin users compared to 42% 
of the 114 controls (p=0.05). Next, in a large retrospective study from 2012, Motzkus-
Feagans et al. found a similarly decreased risk of CDI in statin users (aOR 0.78, 95% CI 
0.75-0.81).53 Of the 31,472 CDI cases, 18% were statin users compared to 22% of the 
78,096 controls. Finally, in 2013, Nseir et al. found that no statin use was significantly 
associated with an increased risk of CDI (OR 2.20, 95% CI 1.82-2.73).54 Of the 197 cases, 
33% were statin users compared to 52% of the 169 controls (p=0.02).  
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STATINS AND CDI OUTCOMES 
To date, three studies on the effect of statin use on CDI outcomes have been 
published.45-47 In 2013, Park et al. were the first to publish data depicting an association 
between statin use and CDI outcomes.45 Of 949 adult CDI patients, 21% were statin users 
receiving therapy for over 12 weeks. There was no significant difference in 30-day all-
cause mortality (RR 1.23, 95% CI 0.59-2.55) or in the proportion of patients with a severe 
complication of CDI (RR 0.85, 95% CI 0.55-1.32); however, the risk of 60-day CDI 
recurrence was significantly lower in statin users (RR 0.39, 95% CI 0.17-0.93).  In 2014, 
Saliba et al. published new data on the risk of 30-day all-cause mortality in CDI associated 
with statin use.46 Of the 1,888 adult CDI patients included in the study, 35% were 
considered current statin users who had filled at least one prescription for a statin in the 90 
days prior. This study found statin use was significantly associated with decreased 
mortality (aOR 0.57, 95% CI 0.42-0.79). In the smallest but most recent study, from 2016, 
assessing the impact of statin use on CDI outcomes, Atamna et al. found that 36% of their 
cohort of 499 adult CDI patients had been on statin therapy within the 3 months prior to 
diagnosis.47 In multivariate analysis, statin use was not significantly associated with 30-
day mortality (OR 1.54, 95% CI 0.85-2.79). 
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Chapter Three: Objectives and Hypotheses 
KNOWLEDGE GAP 
Limited data currently exist in the literature on the outcomes of statin users who 
develop CDI compared with non-users. Of the three studies previously described, only one 
study assessed both 60-day recurrence and 30-day mortality.  A study with a larger sample 
size and more robust methodology is needed to evaluate the association between statin use 
and CDI outcomes (mortality, recurrence, and severity). 
 
OBJECTIVE 1 
The primary objective of this study was to compare CDI health outcomes in statin 
users and non-users in a national cohort of patients from a single-payer health system.   
 
Hypothesis 1a 
Statin use is associated with improved CDI outcomes (inpatient mortality, 30-day 
mortality, 60-day recurrence, and severe or complicated CDI) when compared to 
unmatched non-users.  
 
Hypothesis 1b 
Statin use is associated with improved CDI outcomes (inpatient mortality, 30-day 
mortality, 60-day recurrence, and severe or complicated CDI) when compared to 
propensity-score matched non-users.  
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OBJECTIVE 2 
In a subgroup analysis, evaluate only prior statin users with adherence >60% in the 
past year for CDI outcomes to better explore the impact of long-term (chronic) statin use. 
Evaluate chronic statin users for a dose-response relationship between the degree of LDL 
lowering or the intensity of statin therapy and CDI outcomes.   
 
Hypothesis 2a 
Chronic statin use with an LDL ≥100 mg/dL is associated with poorer CDI 
outcomes (30-day mortality, 60-day recurrence, and severe or complicated CDI) when 
compared to patients with an LDL <100 mg/dL. 
 
Hypothesis 2b 
High intensity chronic statin therapy is associated with improved CDI outcomes 
(30-day mortality, 60-day recurrence, and severe or complicated CDI) when compared to 
low-moderate intensity chronic statin therapy. 
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Chapter Four: Methods 
STUDY DESIGN 
This was a longitudinal, retrospective cohort study of all CDI patients receiving 
care at any of the approximately 150 Veterans Health Administration (VHA) hospitals and 
820 VHA clinics in the U.S. Data for this study were obtained from the Veterans Affairs 
Informatics and Computing Infrastructure (VINCI), which includes administrative, 
clinical, laboratory, and pharmacy data repositories which are linked using unique patient 
identifiers. All data collection and analyses were performed at the South Texas Veterans 
Health Care System, Audie L. Murphy Veterans Affairs (VA) Hospital, San Antonio, TX. 
This study was approved by the Institutional Review Boards at the University of Texas 
Health Science Center San Antonio and the South Texas Veterans Health Care System 
Research and Development Committee. 
 
STUDY POPULATION 
The initial cohort was created by identifying all adult patients (age 18 to 89 years) 
who had any inpatient or outpatient ICD-9-CM code for CDI (008.45) plus any positive 
laboratory value for CDI (Table 1) during the visit or within 7 days of the visit from 
October 1, 2002 through September 30, 2014 (Figure 5). We also included a one-year 
observation window (October 1, 2001 through October 1, 2002) to assess prior 
comorbidities and medication use. For health outcomes, we limited the cohort to those 
patients with CDI between October 1, 2002 through June 30, 2014 to allow for a 90-day 
follow-up window (July 1, 2014 through September 30, 2014). The cohort was limited to 
first episode CDI patients and excluded patients without active CDI treatment. This was 
accomplished by excluding those patients with an ICD-9-CM code for CDI (008.45) in the 
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year prior to study inclusion (observation window). For analyses of the risk of 60-day 
recurrence, we also excluded those who died within 60 days of the end of treatment 
discontinuation for the initial episode to capture only those patients at risk for 60-day 
recurrence. The CDI encounter date, meaning the initial date of inpatient hospitalization or 
outpatient clinic visit during which CDI was diagnosed, was used as the index date for all 
variables unless otherwise noted.  
 
Figure 5. Overview of Study Timeline 
 
STUDY DEFINITIONS 
Patients were divided into two groups, statin users and non-users, based on statin 
exposure prior to and during the CDI encounter. Statin use was a composite variable, 
defined as patients meeting criteria for both prior and concomitant statin use (Table 3). 
Prior statin users were defined as patients who filled at least one prescription for a statin 
medication in the 90 days prior to initial CDI encounter. Concomitant statin use represents 
documented statin use during a CDI episode. Non-users were defined as patients who had 
no prescription history of statins in the 90 days prior to initial CDI encounter or within 14 
days of the CDI treatment start date. These two groups were used for analysis of the 
primary objective. All statin products available in the United States were evaluated for 
Oct 1, 
2001 
Oct 1, 
2002 
Jun 30, 
2014 
Sep 30, 
2014 
1 year of 
observation CDI cohort 
90 days of 
follow-up 
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prescription use (Table 4), and high-intensity statin therapy was defined as atorvastatin 
(Lipitor®) 40-80 mg daily or rosuvastatin (Crestor®) 20-40 mg daily according to 
recommendations published in 2015 by the National Lipid Association.  
 
Table 3. Definitions of Statin Variables 
Variable name Definition Objective accomplished 
Prior statin user Statin prescribed ≥48 hours 
in the 90 days prior to 
initial CDI encounter 
Used to create the statin 
user composite variable 
Concomitant statin user Statin prescribed ≥48 hours 
within 14 days of CDI 
treatment start date 
Used to create the statin 
user composite variable 
Statin user Meets criteria for both 
prior statin user and 
concomitant statin user 
Objective 1 
Non-user No prior statin use and no 
concomitant statin use 
Objective 1 
Long-term/chronic user Statin adherence >60% in 
the 360 days preceding 
first CDI encounter 
Objective 2 
 
Table 4. Statins Currently Available in the United States 
Generic name  Trade name Recommended daily dose 
Atorvastatin  Lipitor® 10-80 mg 
Fluvastatin  Lescol® 20-80 mg 
Lovastatin  Mevacor® 10-80 mg 
Pitavastatin  Livalo® 1-4 mg 
Pravastatin  Pravachol® 10-80 mg 
Rosuvastatin  Crestor® 5-40 mg 
Simvastatin  Zocor® 5-80 mg 
 
In subgroup analyses of the statin-user cohort, statin use was further categorized as 
long-term or chronic statin users if patients had greater than 60% adherence in the year 
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prior to CDI encounter (Table 3). Adherence was defined as the proportion of days covered 
(PDC) in the 360 days preceding the initial CDI encounter and limited to patients with over 
60% adherence based on nationally representative findings from Yeaw et al. showing the 
mean 12-month adherence rate for statins was 61% based on PDC calculations.55 These 
users were then assessed for a dose-response relationship between the degree of cholesterol 
lowering or the intensity of statin therapy and CDI outcomes.  
To better differentiate the effect of statins beyond cholesterol control, we collected 
the patient’s most recent serum low-density lipoprotein (LDL) cholesterol level drawn in 
the year prior to first CDI encounter. The National Lipid Association’s recommendations 
from 2015 for the management of dyslipidemia include a goal LDL level <100 mg/dL as 
desirable for most patients.56 Chronic statin users were stratified based on this threshold to 
assess CDI outcomes in the subgroup analysis.  
Patient demographics included patient age during the initial CDI episode, sex, race, 
and ethnicity. Sex, race, and Hispanic ethnicity were defined as the most common reporting 
of each characteristic over the study period. Tobacco use was defined as ICD-9-CM code 
305.1 or V15.82 or CPT-4 code 99406 or 99407 in year prior to first CDI encounter. 
Principal CDI was defined as ICD-9-CM code 008.45 in the first position. This often 
indicates that CDI was the primary contributor to hospitalization. Secondary CDI was 
defined as ICD-9-CM code 008.45 in any position except first. CDI was also characterized 
by type. Community-associated CDI (CA-CDI) was defined as CDI therapy initiated in the 
outpatient setting or on days 1 or 2 of hospitalization. Community-onset, healthcare 
facility-associated CDI (CO-HCFA-CDI) was defined the same way, with the addition of 
a hospitalization in the prior 90 days. Lastly, healthcare facility-onset CDI (HCFO-CDI) 
was defined as CDI therapy beginning on day 3 or later of hospitalization.  
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We collected Charlson comorbidities and other relevant diagnoses, as defined by 
ICD-9-CM codes, in the year prior to the first CDI episode (Appendix). We also calculated 
the Charlson comorbidity score as described by Deyo et al.57 In addition, we collected other 
infections that occurred during a CDI episode (between CDI episode start date and end of 
CDI therapy), including: bacteremia, pneumonia, skin infection, intra-abdominal infection, 
urinary tract infection, device-related infection, endocarditis, and acute respiratory 
infection (Appendix). Markers of CDI severity that occurred during a CDI encounter were 
also captured, including ICU admission, sepsis/septicemia, shock, acute renal failure, 
megacolon, prolonged ileus, perforated intestine, colectomy, white blood cell count (WBC) 
≥15,000 cells/µL, C-reactive protein (CRP) ≥160 mg/L, serum creatinine (SCr) >1.5 
mg/dL, and albumin <2.5 g/dL.  
CDI-related medication therapy, administered during a CDI episode, could include: 
metronidzazole (oral or intravenous), vancomycin (oral or rectal), fidaxomicin, rifaximin, 
nitazoxanide, IVIG, probiotics, and FMT. Prior and concomitant non-CDI antibiotics 
(excludes oral vancomycin, metronidazole, fidaxomicin, rifaximin, and nitazoxanide), 
non-CDI high-risk antibiotics (third and fourth generation cephalosporins, 
fluoroquinolones, and clindamycin), gastric acid-suppressing (GAS) drugs (antacids, H2-
receptor blockers, proton pump inhibitors), anti-diarrhea medications, narcotics, and bowel 
prep medications were collected. Prior use was defined as any use in the 90 days prior to a 
CDI encounter. Concomitant use was defined as any use during or within 60 days following 
a CDI encounter.  
To minimize potential confounding from a healthy user effect, variables accounting 
for healthcare utilization were collected. These include: 1) ≥1 outpatient visit in the 90-
days prior to initial CDI diagnosis, 2) hospitalization or surgery within the 90-days prior to 
initial CDI diagnosis, 3) receiving chronic dialysis therapy, and 4) residence in a long-term 
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care facility (LTCF). These variables will account for a wider variety of patients at risk of 
exposure to C. difficile spores than is included in the surveillance definition for CO-HCFA-
CDI. History of aspirin and non-statin antilipemic agents (bile acid sequestrants, ezetimibe, 
fibric acids, and niacin) used in the 90 days prior to the initial CDI encounter was also 
collected.  
Mortality was defined as death from any cause during inpatient hospitalization or 
within 30 days following CDI treatment discontinuation. Severe or complicated CDI was 
defined as the presence of at least one CDI severity indicator as described above. A 
recurrence was defined as a second outpatient or inpatient visit during which a patient 
received an ICD-9-CM code for CDI with a minimum 3-day gap between the visit and the 
end of active CDI therapy for the initial episode. As in previous studies, 60-day recurrence 
was used as a specific endpoint.  
 
DATA AND STATISTICAL ANALYSES 
Data extraction and variable creation were conducted using SAS Version 9.4® 
(SAS Institute, Cary, NC, USA). Propensity score matching was performed using STATA 
14® (StataCorp, College Station, TX, USA). All other data and statistical analyses were 
conducted using JMP 13® (SAS Institute, Cary, NC, USA).  
All independent and dependent variables were first presented descriptively. 
Variables that were absent from the medical chart (e.g., comorbidities) were assumed to 
have not occurred. Patient demographics and medication use were characterized during the 
baseline period. Categorical variables were described as number (percentage) and 
continuous variable were described as median (interquartile range, IQR).  
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Objective 1: Hypothesis 1a 
For the primary analysis of the unmatched cohort, we entered baseline 
characteristics  known to impact statin use, also included in the propensity score (Table 5), 
and variables known to affect CDI outcomes (Table 6) into a multivariable logistic 
regression model in order to determine the risk of individual CDI outcomes. Variables with 
less than 5% of the cohort were not entered into the model to improve model stability. The 
dependent variables collectively referred to as CDI outcomes included inpatient mortality, 
30-day mortality, 60-day recurrence, and severe or complicated CDI. An adjusted odds 
ratios (aOR) and 95% confidence interval (95% CI) was calculated using logistic 
regression for each CDI outcome.  
 
Objective 1: Hypothesis 1b 
For the primary analysis of the matched cohort, we created a propensity score-
matched cohort to account for the variables associated with indications for statin use. 
Propensity scores were created using a multivariable logistic regression model. We then 
performed nearest neighbor matching (1:1) with a caliper of 0.2. Over 40 variables were 
considered for the derivation of the propensity scores (Table 5); these variables were 
included because they could affect the likelihood of a patient receiving a statin or affect the 
patient’s statin use. Once the matched cohort was derived, variables known to impact CDI 
outcomes (Table 6) were entered into a multivariable logistic regression model in order to 
determine the risk of individual CDI outcomes. Variables with less than 5% of the cohort 
were not entered into the propensity score model or CDI outcomes models in order to 
improve model stability. Finally, an aOR and 95% CI was calculated using logistic 
regression for each CDI outcome.  
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Table 5. Variables Included in the Propensity Score 
Baseline characteristic 
Age (continuous) 
Gender  
Race 
Ethnicity 
Fiscal year of initial CDI encounter 
VHA priority group  
Tobacco use 
LDL (continuous) 
Comorbidities, present in at least 5% of cohort (21 possible) 
Aspirin therapy 
Non-statin antilipemic therapy  
Healthcare utilization (4) 
 
Table 6. Variables Associated with CDI Outcomes 
Patient characteristic 
Principal CDI 
CDI surveillance type  
Concomitant infections, present in at least 5% of cohort (8 possible) 
CDI severity indicators, present in at least 5% of cohort (12 possible) 
Prior medication (antibiotics, GAS) 
Concomitant medication (narcotics, anti-diarrheals, bowel prep)  
CDI-related medication (metronidazole, vancomycin, probiotics) 
 
Objective 2: Hypothesis 2a 
Subgroup analyses were conducted using a cohort of long-term (chronic) statin 
users defined as prior statin users with at least 60% adherence in the year prior to the CDI 
encounter. These users were stratified by the patient’s LDL value (<100 mg/dL or ≥100 
mg/dL) to assess for a dose-response relationship between the degree of cholesterol 
lowering and CDI outcomes. Risk was calculated using multivariable logistic regression 
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(Table 7) in which LDL <100 mg/dL was used as the reference. Variables with less than 
5% of the cohort were not entered into the model to improve model stability. 
 
Objective 2: Hypothesis 2b 
Chronic users were also stratified by the intensity of the statin regimen to assess for 
a dose-response relationship between the intensity of the statin and CDI outcomes. Risk 
was calculated using multivariable logistic regression (Table 7) in which low-moderate 
intensity statin therapy was used as the reference. Variables with less than 5% of the cohort 
were not entered into the model to improve model stability. 
 
Table 7. Variables Included in the Chronic User Models 
Patient characteristic 
Age (continuous) 
Gender  
Race 
Ethnicity 
Fiscal year of initial CDI encounter 
VHA priority group  
Tobacco use 
Comorbidities, present in at least 5% of cohort (21 possible) 
Aspirin therapy 
Non-statin antilipemic therapy  
Healthcare utilization (4) 
Principal CDI 
CDI surveillance type  
Concomitant infections, present in at least 5% of cohort (8 possible) 
CDI severity indicators, present in at least 5% of cohort (12 possible) 
Prior medication (antibiotics, GAS) 
Concomitant medication (narcotics, anti-diarrheals, bowel prep)  
CDI-related medication (metronidazole, vancomycin, probiotics) 
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Chapter Five: Results 
COHORT DESCRIPTION 
The overall cohort meeting study inclusion criteria contained 24,813 VHA 
enrollees diagnosed and treated for CDI. Of these patients, only 2.8% met criteria as a statin 
user. Due to VHA formulary restrictions, the statins prescribed were limited to pravastatin 
and rosuvastatin. Overall, the population was predominately elderly, non-Hispanic, white 
males (Table 8). Patients were primarily categorized with HCFO-CDI, and the most 
common concomitant infections were pneumonia and skin infection. Notably, 
complications of CDI (megacolon, ileus, perforated intestine, and colectomy) were rare 
events, occurring in less than 5% of the patient population.  
Characteristics of statin users and non-users were recorded before and after 
propensity-score matching was performed (Table 8).  In both the statin user and non-user 
groups, the majority of patients had an LDL level in a desirable range. The final propensity 
score included 26 variables (Table 8). Comorbidities were included if present in at least 
5% of the unmatched population. These included: hypertension, dyslipidemia, obesity, 
myocardial infarction, congestive heart failure, peripheral vascular disease, 
cerebrovascular disease, COPD, diabetes, renal disease, neoplastic disease, and GERD. 
Approximately 26% of all statin users were retained after propensity score matching was 
performed (Table 8). In the matched cohort, over 90% of patients had a diagnosis of 
dyslipidemia in each group and 10% had a prior prescription for a non-statin antilipemic 
agent.  
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Table 8. Characteristics of Unmatched and Matched Cohorts 
 Unmatched Cohort Matched Cohort 
Characteristic Statin 
users 
n=699 
Non-users 
n=24,114 
Statin 
users 
n=181 
Non-users 
n=181 
Age (years), median (IQR)* 68 (63-77) 68 (60-79) 66 (63-75) 68 (63-77) 
Male sex, n (%)* 679 (97.1) 23,115 (95.9) 177 (97.8) 179 (98.9) 
White, n (%)* 500 (71.5) 17,286 (71.7) 133 (73.5) 130 (71.8) 
Black, n (%)* 158 (22.6) 4,993 (20.7) 39 (21.5) 46 (25.4) 
Hispanic, n (%)* 31 (4.4) 1,295 (5.4) 9 (5.0) 9 (5.0) 
Priority group, median (IQR)* 5 (2-5) 5 (3-5) 5 (2-5) 5 (2-5) 
LDL (mg/dL), median (IQR)* 79 (63-104) 85 (66-108) 83 (65-107) 76 (60-97) 
Smoker, n (%)* 219 (31.3) 5,743 (23.8) 63 (34.8) 48 (26.5) 
Principal CDI, n (%) 226 (32.3) 7,383 (30.6) 57 (31.5) 52 (28.7) 
CDI type, n (%)     
     CA-CDI 115 (16.5) 4,968 (20.6) 26 (14.4) 30 (16.6) 
     CO-HCFA-CDI 143 (20.5) 5,530 (22.9) 40 (22.1) 53 (29.3) 
     HCFO-CDI 441 (63.0) 13,616 56.5) 115 (63.5) 98 (54.1) 
Comorbidities, n (%)     
     Hypertension* 639 (91.4) 18,428 (76.4) 161 (90.0) 163 (90.0) 
     Dyslipidemia* 618 (88.4) 12,524 (51.9) 164 (90.1) 170 (93.9) 
     Obesity* 179 (25.6) 3,801 (15.8) 55 (30.4) 57 (31.5) 
     Myocardial infarction* 128 (18.3) 2,539 (10.5) 31 (17.1) 28 (15.5) 
     Congestive heart failure* 271 (38.8) 6,100 (25.3) 58 (32.0) 64 (35.4) 
     Peripheral vascular disease* 209 (29.9) 4,364 (18.1) 48 (26.5) 51 (28.2) 
     Cerebrovascular disease* 208 (29.8) 4,469 (18.5) 52 (28.7) 39 (21.5) 
     Dementia 24 (3.4) 930 (3.9) 3 (1.7) 6 (3.3) 
     COPD* 276 (39.5) 9,029 (37.4) 56 (30.9) 60 (33.1) 
     Rheumatologic disease 21 (3.0) 656 (2.7) 4 (2.2) 2 (1.1) 
     Peptic ulcer disease 25 (3.6) 1,143 (4.7) 3 (1.7) 7 (3.9) 
     Liver disease 20 (2.9) 1,773 (7.4) 5 (2.8) 8 (4.4) 
     Diabetes*  437 (62.5) 9,358 (38.8) 109 (60.2) 113 (62.4) 
     Hemi-/paraplegia 33 (4.7) 928 (3.8) 11 (6.1) 8 (4.4) 
     Renal disease*  282 (40.3) 6,459 (26.8) 65 (35.9) 62 (34.3) 
     Neoplastic disease* 195 (27.9) 6,982 (29.0) 53 (29.3) 50 (27.6) 
     HIV/AIDS 16 (2.3) 422 (1.8) 4 (2.2) 2 (1.1) 
     GERD* 218 (31.2) 6,288 (26.1) 58 (32.0) 62 (34.3) 
     Transplant 27 (3.9) 429 (1.8) 6 (3.3) 6 (3.3) 
     Inflammatory bowel disease 10 (1.4) 546 (2.3) 4 (2.2) 5 (2.8) 
     Irritable bowel syndrome 8 (1.1) 260 (1.1) 2 (1.1) 2 (1.1) 
 
 26 
Table 8. Characteristics of Unmatched and Matched Cohorts, cont. 
 
Charlson score, median (IQR) 4 (3-7) 3 (2-6) 4 (2-6) 4 (3-6) 
Concomitant infections, n (%)     
     Bacteremia 62 (8.9) 1,765 (7.3) 16 (8.8) 13 (7.2) 
     Pneumonia 165 (23.6) 5,782 (24.0) 32 (17.7) 39 (21.5) 
     Skin infection 101 (14.4) 2,787 (11.6) 20 (11.1) 24 (13.3) 
     Intra-abdominal infection 52 (7.4) 1,489 (6.2) 13 (7.2) 14 (7.7) 
     Device-related infection 27 (3.9) 838 (3.5) 5 (2.8) 2 (1.1) 
     Acute respiratory infection 33 (4.7) 936 (3.9) 8 (4.4) 2 (1.1) 
     Endocarditis 15 (2.1) 259 (1.1) 2 (1.1) 2 (1.1) 
     Urinary tract infection 19 (2.7) 456 (1.9) 6 (3.3) 4 (2.2) 
CDI severity indicators, n (%)     
     ICU admission 12 (1.7) 899 (3.7) 2 (1.1) 4 (2.2) 
     Sepsis/septicemia 160 (22.9) 4,347 (18.0) 41 (22.7) 39 (21.5) 
     Shock 52 (7.4) 1,252 (5.2) 14 (7.7) 7 (3.9) 
     Acute renal failure 311 (44.5) 7,554 (31.3) 80 (44.2) 58 (32.0) 
     Megacolon 2 (0.3) 82 (0.3) 0 0 
     Ileus 29 (4.1) 1,016 (4.2) 7 (3.9) 6 (3.3) 
     Perforated intestine 6 (0.9) 123 (0.5) 3 (1.7) 2 (1.1) 
     Colectomy 0 37 (0.2) 0 1 (0.6) 
     WBC ≥15,000 cells/µL 343 (49.1) 10,347 (42.9) 84 (46.4) 87 (48.1) 
     CRP ≥160 mg/L 17 (2.4) 426 (1.8) 4 (2.2) 3 (1.7) 
     Albumin <2.5 g/dL 286 (40.9) 8,834 (36.6) 69 (38.1) 79 (43.6) 
     SCr >1.5 mg/dL 224 (32.0) 5,746 (23.8) 44 (24.3) 46 (25.4) 
Prior medications, n (%)     
     Antibiotics 413 (59.1) 13,312 (55.2) 99 (54.7) 107 (61.9) 
     High-risk antibiotics 272 (38.9) 8,990 (37.3) 68 (37.6) 74 (40.9) 
     GAS drugs 476 (68.1) 13,256 (55.0) 121 (66.9) 110 (60.8) 
     Narcotics 312 (44.6) 9,035 (37.5) 82 (45.3) 93 (51.4) 
     Anti-diarrheals 46 (6.6) 1,747 (7.2) 8 (4.4) 12 (6.6) 
     Bowel prep 150 (21.5) 3,537 (14.7) 38 (21.0) 48 (26.5) 
     Aspirin use* 332 (47.5) 6,533 (27.1) 82 (45.3) 78 (43.1) 
     Non-statin antilipemic* 50 (7.2) 757 (3.1) 18 (9.9) 18 (9.9) 
Conc. medications, n (%)     
     Antibiotics 535 (76.5) 18,150 (75.3) 132 (72.9) 139 (77.0) 
     High-risk antibiotics 378 (54.1) 12,767 (52.9) 95 (52.5) 97 (53.6) 
     GAS drugs 585 (83.7) 19,102 (79.2) 150 (82.9) 143 (79.0) 
     Narcotics 400 (57.2) 12,174 (50.1) 110 (60.8) 106 (58.6) 
     Anti-diarrheals 67 (9.6) 2,773 (11.5) 18 (9.9) 17 (9.4) 
     Bowel prep 169 (24.2) 4,597 (19.1) 51 (28.2) 46 (25.4) 
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Table 8. Characteristics of Unmatched and Matched Cohorts, cont. 
 
CDI-related medications, n (%)     
     Metronidazole 631 (90.3) 20,822 (86.3) 162 (89.5) 143 (79.0) 
     Oral vancomycin 359 (51.4) 10,454 (43.4) 86 (47.5) 91 (50.3) 
     Fidaxomicin 10 (1.4) 144 (6.0) 3 (1.7) 3 (1.7) 
     Probiotics 226 (32.3) 6,726 (27.9) 54 (29.8) 55 (30.4) 
Healthcare utilization, n (%)*     
     Prior outpatient visit  687 (98.3) 22,386 (92.8) 178 (98.3) 179 (98.9) 
     Prior hospitalization or  
     surgery  
531 (76.0) 15,733 (65.2) 140 (77.3) 142 (78.5) 
     Chronic dialysis therapy 36 (5.1) 676 (2.8) 8 (4.4) 3 (1.7) 
     Residence in LTCF 109 (15.6) 3,005 (12.5) 24 (13.3) 29 (16.0) 
*Denotes variables included in propensity score  
 
OBJECTIVE 1: CDI OUTCOMES 
CDI outcomes were evaluated for statin users and non-users before and after 
propensity score-matching (Table 9). The logistic regression model for the unmatched 
cohort included all factors used in the derivation of the propensity scores in addition to all 
the factors used in the matched cohort regression model. In the unmatched cohort, statin 
use was significantly associated with a reduced risk of 30-day mortality (aOR 0.60, 95% 
CI 0.36-1.00, p=0.0478). No significant associations were noted for inpatient mortality, 
60-day recurrence, and severe or complicated CDI in the unmatched cohort.  
In the matched cohort, statin use remained significantly associated with a reduced 
risk of 30-day mortality (aOR 0.45, 95% CI 0.23-0.88, p=0.0198). No significant trends 
were found for inpatient mortality, 60-day recurrence, and severe or complicated CDI in 
the matched cohort. In both the unmatched and matched cohorts, a non-significant 
association exists for a decreased risk of 60-day recurrence in statin users. 
 
 
 28 
Table 9. CDI Outcomes among Statin Users and Non-users 
 Statin users Non-users 
(reference) 
aOR (95% CI) p-value 
Unmatched cohort (statin users, n=699; non-users, n=24,114)  
Inpatient mortality 68 (9.7) 2,291 (9.5) 1.18 (0.66-2.13) 0.5783 
30-day mortality 147 (21.0) 5,483 (22.7) 0.60 (0.36-1.00) 0.0478 
60-day recurrencea 45 (8.6) 
n=525 
2,341 (13.3) 
n=17,645 
0.71 (0.39-1.28) 0.2577 
Severe or complicated 558 (79.8) 17,028 (70.6) 1.01 (0.67-1.51) 0.9708 
Propensity score-matched cohort (statin users, n=181; non-users, n=181)  
Inpatient mortality 16 (8.8) 14 (7.7) 1.11 (0.44-2.76) 0.8267 
30-day mortality 23 (12.7) 41 (22.7) 0.45 (0.23-0.88) 0.0198 
60-day recurrencea,b  14 (9.3) 
n=151 
19 (14.4) 
n=132 
0.84 (0.35-2.00) 0.6941 
Severe or complicated 138 (76.2) 139 (76.8) 0.95 (0.53-1.70) 0.8680 
aExcludes patients with 60-day mortality  
bNot adjusted for shock due to model instability 
 
OBJECTIVE 2: CHRONIC USERS AND CHOLESTEROL LEVEL  
Prior statin users with at least 60% adherence in the year prior to the CDI encounter 
were assessed for a dose-response relationship between the degree of cholesterol-lowering 
and CDI outcomes (Table 10). Of the chronic statin users (n=1,104), approximately 21% 
had an undesirable or elevated LDL. In multivariate analysis, no significant association 
was found between LDL ≥100 mg/dL and the CDI outcomes assessed.  
 
OBJECTIVE 2: CHRONIC USERS AND STATIN INTENSITY 
Patients meeting criteria for chronic statin use (n=1,221) were stratified by intensity 
of the statin therapy. Approximately 30% of chronic users were on high intensity therapy 
and were assessed for a dose-response relationship between the degree of statin intensity 
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and CDI outcomes (Table 10). In multivariate analysis, no significant association was 
found for high intensity therapy and each CDI outcome evaluated. 
 
Table 10. CDI Outcomes for Chronic Statin Users 
 
  
Outcome 30-day mortality 60-day recurrencea Severe or complicated 
 n (%) aORb 
(95% CI) 
n (%) aOR 
(95% CI) 
n (%) aOR 
(95% CI) 
LDL (mg/dl), n=1,104 
<100  
(n=871) 
154/871 
(17.7) 
Reference 
1.00 
129/691 
(18.7) 
Reference 
1.00 
621/871 
(71.3) 
Reference 
1.00 
≥100  
(n=233) 
32/233 
(13.7) 
0.43  
(0.10-1.75) 
40/194 
(20.6) 
1.09  
(0.44-2.67) 
160/233 
(68.7) 
0.74  
(0.34-1.61) 
Statin intensity, n=1,221 
Low-mod. 
(n=855) 
149/855 
(17.4) 
Reference 
1.00 
125/673 
(18.6) 
Reference 
1.00 
604/855 
(70.6) 
Reference 
1.00 
High 
(n=366) 
58/366 
(15.9) 
0.71  
(0.25-2.02)  
61/300  
(20.3) 
1.12 
(0.50-2.50) 
262/366 
(71.6) 
1.03  
(0.53-2.01) 
aExcludes patients with 60-day mortality  
bNot adjusted for gender, ethnicity, and prior outpatient visit due to model instability 
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Chapter Six: Discussion 
OBJECTIVE 1 
From 2000 to 2014, a total of 24,813 VHA enrollees were diagnosed and treated 
for CDI. Of these patients, 699 VHA enrollees had a history of prior statin use and 
continued concomitant statin use during CDI infection while 24,114 VHA enrollees were 
considered statin non-users. After propensity score matching, the cohort was limited to 181 
statin users and 181 non-users. In both the unmatched and matched cohorts, statin use was 
significantly associated with a reduced risk of 30-day mortality. Additionally, no 
significant associations were found for inpatient mortality, 60-day recurrence, and severe 
or complicated CDI. In both the unmatched and matched cohorts, a non-significant 
association exists for a decreased risk of 60-day recurrence in statin users. In subgroup 
analyses of chronic statin users, LDL level and intensity of statin therapy were not 
significantly associated with mortality, recurrence, and severe or complicated CDI.  
Compared to prior literature on this topic, our study has the largest overall patient 
cohort reported spanning the longest period of time. Due to strict criteria in the definition 
of statin users and the use of propensity score matching with replacement, the final matched 
cohort was limited to only 1.4% of our CDI cohort for the matched analyses. Despite the 
reduced population size, the risk of 30-day mortality was found to be significantly reduced 
in the statin user population compared to non-users. Additionally, statin use appears to be 
associated with a non-significant reduction in risk of 60-day recurrence. 
Overall, the inpatient mortality rate in our study of 10% and the 30-day mortality 
rate of approximately 20% are in line with contemporary epidemiological data for CDI. In 
a 2012 literature review of all-cause mortality in hospitalized patients with CDI in the 
northern hemisphere, researchers found 30-day mortality varied from 9% to 38% and in-
hospital mortality ranged from 8% to 37%.58 Our 30-day mortality rates for the matched 
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statin users and non-users (13% vs. 23%) are very similar to those reported by Saliba et al. 
(13% vs. 21%, p<0.001), making our study the second to report finding a significant 
reduction in risk of 30-day mortality associated with statin use.46  
In the two other studies published on this topic, Atamna et al. and Park et al. both 
found statins were not significantly associated with 30-day mortality or severity using 
multivariate logistic regression.45,47 Additionally, these two studies are limited in that they 
both only utilized unmatched data from a single hospital and did not collect data regarding 
statin regimens. The study by Park et al. was the only prior study to look at 60-day 
recurrence rates.45 Although they found a significantly reduced rate of recurrence 
associated with statin use compared to non-users (3% vs. 7%, p=0.033), the association 
was not seen in our study (9% vs. 14%, p=0.6941). The reasons for this are unclear, but are 
likely related to differences in study design as opposed to any clinical mechanism 
underlying this hypothetical effect.  
 
OBJECTIVE 2 
Unlike the findings from Saliba et al., our study did not find a dose-response effect 
when assessing the impact of long-term or chronic statin use on mortality.46 One 
explanation for this, is that our study used a more rigorous definition of long-term users by 
assessing adherence to statin therapy in the year prior to the first CDI episode whereas 
Saliba et al. only looked at number of prescriptions filled.  
In our secondary analysis of chronic users, neither statin intensity nor LDL level 
appeared to be significantly with any CDI outcomes. This analysis, though limited by our 
small sample size, did find a non-significant reduction in 30-day mortality associated high-
intensity chronic statin use. Given the lack of findings regarding a dose-response 
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relationship between chronic statin therapy and CDI outcomes, the mechanism for statins’ 
protective effects is likely unrelated to the cholesterol-lowering effects and the cholesterol-
lowering potency of the statin therapy.  
Contrary to our hypothesis, chronic statin users with elevated cholesterol or 
undesirable LDL levels (≥100 mg/dL) appeared to have no increased risk associated with 
CDI outcomes. In addition to the small sample size, it is possible that if an effect exists it 
can only be seen at much greater extremes of cholesterol levels.   
 
STRENGTHS 
This study has multiple strengths. First, we collected data on all patients with CDI 
managed at any VHA facility over a 12-year period. The VHA is a closed healthcare system 
with pharmacy data available for all prescriptions filled within the system. Our definition 
for prior statin use was similar to that used in previous studies; however, statin users in our 
study were ultimately limited to those with continued use during a CDI encounter to ensure 
chronic and recent receipt of statin therapy relative to the acquisition of CDI. This ensured 
no significant lapse in statin therapy prior to the CDI encounter. Additionally, propensity-
score matching was used to minimize confounding, including the potential for a healthy 
user effect. Ours is the only study on this topic to utilize a matched design to compare statin 
users and non-users with CDI. 
Second, the VHA maintains a comprehensive computerized system, which allowed 
for the collection of data on inpatient and outpatient CDI diagnoses and outcomes. By 
reviewing patient history for a year prior to CDI diagnosis and for 90 days after, we were 
able to distinguish first episodes from recurrences. Furthermore, the inclusion of only 
patients with an ICD-9 code for CDI who received CDI therapy and had a positive CDI 
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laboratory test result minimized the possibility of misclassification seen with 
administrative coding alone. 
 
LIMITATIONS 
This study is limited by the use of extracted medical data, and a retrospective cohort 
study design. All data collection relied on electronic medical records, and no individual 
chart reviews were performed. Cohort studies might be subject to misclassification bias 
and confounding by unmeasured variables. Similarly, comorbidities might not be fully 
captured using administrative codes and cannot be considered equivalent to medical chart 
reviews. Additionally, electronic medical data are created for the purpose of patient care, 
not for research, and might contain errors.  
Although several CDI morbidity and mortality risk factors were included in the 
logistic regression models, additional factors exist that are not included in the analysis. For 
example, specific C. difficile ribotypes are associated with increased virulence.8 
Additionally, we were unable to assess all medications a patient was prescribed. Patients 
could have been on additional agents not accounted for that could modify a patient’s risk 
for development of CDI as well as a patient’s CDI outcomes. Physician attitudes and 
prescribing preferences could also impact a patient’s risk for development CDI, 
promptness of treatment, and risk for recurrent episodes. Furthermore, the predominately 
elderly, male, veteran CDI population might not be representative of all CDI populations, 
limiting the generalizability of our findings.  
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CONCLUSIONS 
The results of our study are unable to yield recommendations for changes directly 
impacting routine care of CDI patients. The clinical significance of our findings is 
unknown due to many factors. First, the mechanisms underlying these results are 
theoretical. Second, these results can only be generalized to patients meeting our study 
criteria with a history of statin use prior to CDI and continued use during infection. It is 
unknown what effect, if any, initiating statin therapy during CDI could have on CDI 
outcomes. Third, the effect of chronic statin therapy on CDI outcomes appears unrelated 
to the cholesterol-lowering effects and the cholesterol-lowering potency of the statin 
therapy.  
To date, this is the largest study comparing CDI health outcomes among statin users 
and non-users. Statin users were found to have significantly reduced 30-day mortality in 
both an unmatched and matched patient cohort compared to non-users. While these data 
support previous findings reported in the literature, no change in routine care of CDI 
patients can be recommended at this time.  
 
FUTURE RESEARCH 
Additional studies on the effects of statins on CDI outcomes may be warranted, but 
will likely elucidate no new information without a randomized controlled trial. Instead, 
future studies evaluating the impact of statin therapy on other non-cardiac conditions are 
recommended to further explore the potential benefits of the pleiotropic effects seen with 
this class of medication. 
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Appendix 
Patient variable ICD-9-CM code(s)  
Comorbidities in year prior to CDI episode 
Hypertension 401-405 
Dyslipidemia 272 
Obesity 278 
Myocardial infarction 410, 412 
Congestive heart failure 428 
Peripheral vascular disease 441, 443.9, 785.4, V43.4 
Cerebrovascular disease 430-438 
Dementia 290 
COPD 490-496, 500-505, 506.4 
Rheumatologic disease 710.0-710.1, 710.4, 714.0-714.2, 714.81, 725 
Peptic ulcer disease 531.0-531.9, 532.0-532.9, 533.0-533.9, 534.0-534.9 
Liver disease 571.2, 571.4, 571.5, 571.6, 572.2-572.8, 456.0-456.21 
Diabetes  250.0-250.3, 250.4, 250.5, 250.6, 250.7, 250.8, 250.9 
Hemiplegia or paraplegia 342, 344.1 
Renal disease  582, 583, 585, 586, 588 
Neoplastic disease 140-172, 174-208 
HIV/AIDS 42-44, V08 
GERD 530.11, 530.81 
Transplant V42, E878.0 
Inflammatory bowel disease 555, 556 
Irritable bowel syndrome 564.1 
Concomitant infections  
Bacteremia 790.7 
Pneumonia 480.0-483.99, 485–487 
Skin infection 680-686  
Intra-abdominal infection 540–543, 562, 567, 569, 574–577 
Urinary tract infection 590-599 
Device-related infection 996.31, 996.62, 996.64, 999.31 
Acute respiratory infection 460-466 
Endocarditis 421.0, 421.1, 421.9, 424.9 
CDI severity indicators 
Shock 639.5, 785.52, 785.59 
Sepsis/septicemia 020.2, 038.0-038.9, 995.91, 995.92 
Perforation of intestine 569.83 
Prolonged ileus 560.1 
Megacolon 558.2, 564.7 
Acute renal failure 584, 586 
Colectomy 45.73, 45.81-83 (procedure codes) 
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Glossary 
Acronym Definition 
CDI Clostridium difficile Infection 
CO-CDI Community-Onset CDI 
CO-HCFA-CDI Community-Onset, Healthcare Facility-Onset CDI 
COPD Chronic Obstructive Pulmonary Disease 
CRP C-Reactive Protein 
FDA United States Food and Drug Administration 
FMT Fecal Microbiota Transplantation 
GAS Gastric Acid-Suppressing 
GDH Glutamate Dehydrogenase 
GERD Gastroesophageal Reflux Disease 
GI Gastrointestinal 
HCFO-CDI Healthcare Facility-Onset CDI 
HIV/AIDS Human Immunodeficiency Syndrome/Acquired Immune Deficiency 
Syndrome 
HLD hyperlipidemia 
HMG-CoA 3-hydroxyl-3-methylgutarul-coenzyme A 
ICD-9-CM International Classification of Diseases, 9th Revision, Clinical 
Modification 
IBD Inflammatory Bowel Disease 
ICU Intensive Care Unit 
IDSA Infectious Diseases Society of America 
IQR Interquartile Range 
IVIG Intravenous Immunoglobulin 
LDL Serum Low-Density Lipoprotein Cholesterol 
LOS Length Of Stay 
LTCF Long-Term Care Facility 
NCEP National Cholesterol Education Program 
NIH National Institutes of Health 
OR Odds Ratio 
PCR Polymerase Chain Reaction 
PDC Proportion of Days Covered  
SCr Serum Creatinine 
US United States  
VA Veterans Affairs 
VHA Veterans Health Administration 
VINCI VA Informatics and Computing Infrastructure 
WBC White Blood Cells 
95% CI 95% Confidence Interval 
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